Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

A new generation of antithrombotic agents, which are conventionally known as direct oral
anticoagulants (DOACs), have recently emerged and are continuing to be developed. These …

Oral vitamin K anticoagulation (warfarin, Coumadin, coumarin) has long been used for long-
term treatment and prophylaxis in a variety of clinical settings. Given the unpredictable …

Essentials• Prothrombin and partial thromboplastin time (PT/PTT) measure direct oral
anticoagulants (DOACs).• PT, PTT and specific tests for DOACs were performed on patients …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

The introduction of direct oral anticoagulant (DOAC) therapy into clinical use in the past 5
years has had significant impact on the clinical laboratory. Clinicians' desire to determine …

The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …